Myriad Genetics (NASDAQ:MYGN) Issues Q4 2024 Earnings Guidance

by · The Markets Daily

Myriad Genetics (NASDAQ:MYGN – Get Free Report) updated its fourth quarter 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.030-0.040 for the period, compared to the consensus EPS estimate of 0.030. The company issued revenue guidance of $209.0 million-$211.0 million, compared to the consensus revenue estimate of $212.8 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on MYGN shares. UBS Group started coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 target price on the stock. Leerink Partners lowered shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. Bank of America reduced their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. Finally, Morgan Stanley reduced their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.27.

Read Our Latest Research Report on MYGN

Myriad Genetics Stock Performance

NASDAQ MYGN opened at $13.87 on Wednesday. The company’s 50 day moving average is $15.05 and its 200-day moving average is $22.17. Myriad Genetics has a 12-month low of $12.87 and a 12-month high of $29.30. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.26 billion, a P/E ratio of -10.67 and a beta of 1.89.

Myriad Genetics Company Profile

(Get Free Report)

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

See Also